Cardioprotective effects of trimetazidine and a combination of succinic and malic acids in acute myocardial ischemia.
A mixture of mitochondrial substrates of succinic and malic acids more effectively than antihypoxant trimetazidine prevented functional and metabolic disorders in rat myocardium during acute ischemia: reduces T wave amplitude, QT interval, number and duration of arrhythmias, and restores oxidation-phosphorylation coupling.
Khazanov
V A
VA
Laboratory of Molecular Pharmacology with a Group of Pharmacokinetics, Institute of Pharmacology, Tomsk Research Center, Siberian Division of Russian Academy of Medical Sciences, Tomsk, Russia. vkh@pharm.tsu.ru
Kiseliova
A A
AA
Vasiliev
K Yu
KY
Chernyschova
G A
GA
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D054059:Coronary Occlusion / Q000503:physiopathology; D004338:Drug Combinations; D004562:Electrocardiography; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D008293:Malates / Q000627:therapeutic use*; D008297:Male; D008929:Mitochondria, Heart / Q000187:drug effects / Q000378:metabolism; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D010085:Oxidative Phosphorylation / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D019802:Succinic Acid / Q000627:therapeutic use*; D013610:Tachycardia / Q000188:drug therapy; D014292:Trimetazidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D002316:Cardiotonic Agents; D004338:Drug Combinations; D008293:Malates; D014665:Vasodilator Agents; C030298:malic acid; D019802:Succinic Acid; D014292:Trimetazidine